Why Was PCOS Renamed to PMOS? The Reason Behind the Name Change, Explained by Experts
Polycystic ovary syndrome (PCOS) has officially been renamed after 14 years of international research, and patients are searching for answers about what the change means for diagnosis and care.
What Is PCOS Now Called, and Why Was the Name Changed?
PCOS has been renamed Polyendocrine Metabolic Ovarian Syndrome, or PMOS, according to a global consensus study published in The Lancet. Researchers concluded the original name was misleading because many patients do not actually have ovarian cysts, and the condition involves far broader endocrine and metabolic dysfunction.
The renaming was led by Professor Helena Teede, director of Monash University’s Monash Centre for Health Research & Implementation and an endocrinologist at Monash Health. The effort took 14 years and involved 56 medical, scientific and patient advocacy organizations, along with feedback from more than 14,000 patients and health professionals worldwide.
“What we now know is that there is actually no increase in abnormal cysts on the ovary, and the diverse features of the condition were often unappreciated,” Teede said, per Endocrine Society. “It was heartbreaking to see the delayed diagnosis, limited awareness and inadequate care afforded those affected by this neglected condition.”
What Is PMOS, Formerly Known as Polycystic Ovary Syndrome?
Polyendocrine Metabolic Ovarian Syndrome (PMOS) — formerly known as Polycystic Ovary Syndrome — is a hormonal imbalance that occurs when the ovaries produce excess hormones, according to Cleveland Clinic.
People with PMOS have ovaries that produce unusually high levels of androgens, which causes reproductive hormones to become imbalanced. As a result, patients often experience irregular menstrual cycles, missed periods and unpredictable ovulation, Cleveland Clinic explains.
Small follicle cysts — fluid-filled sacs containing immature eggs — may appear on the ovaries during an ultrasound due to a lack of ovulation, a condition called anovulation. But cysts are not required for a diagnosis.
The study describes PMOS as a multisystem disorder with significant long-term health and economic impacts. Although the condition has traditionally been viewed as gynecological or ovarian, newer research shows it is driven by broader endocrine and hormonal dysfunction involving insulin, androgens, neuroendocrine hormones and ovarian hormones.
PMOS can affect multiple body systems and present with a wide range of symptoms, the study notes:
- Metabolic symptoms: obesity, insulin resistance, type 2 diabetes, high blood pressure, abnormal cholesterol, fatty liver disease, cardiovascular disease and sleep apnea
- Reproductive symptoms: irregular menstrual cycles, infertility, pregnancy complications and increased endometrial cancer risk
- Psychological symptoms: depression, anxiety, eating disorders and reduced quality of life
- Dermatological symptoms: acne, hair thinning and excess facial or body hair
People with the condition tend to have a higher average BMI, which can worsen symptom severity, the study reports.
The condition affects an estimated 170 million women of reproductive age worldwide — roughly one in eight women, according to the research. Yet up to 70% of affected individuals remain undiagnosed.
“The broad clinical features of the condition are not captured in its current name, as although arrested follicular development is common, pathological ovarian cysts are not increased,” the study reads. “These factors delay diagnosis — with up to 70% of affected individuals remaining undiagnosed — and also contribute to widespread knowledge gaps and patient dissatisfaction.”
That gap in awareness and accurate naming is what drove researchers to push for the change after more than a decade of work.
How Is PMOS Diagnosed in Adults and Adolescents?
PMOS is diagnosed only after ruling out other possible disorders, and the criteria differ based on age, according to the study.
In adults age 20 and older, diagnosis requires at least two of three criteria: irregular or absent ovulation (known as oligo-anovulation); elevated androgen levels or symptoms of excess androgens, called hyperandrogenism; and polycystic ovaries on ultrasound or elevated anti-Müllerian hormone (AMH) levels.
In adolescents ages 10 to 19, diagnosis requires two specific criteria: irregular ovulation and hyperandrogenism. Ultrasound findings are not used to diagnose the condition in younger patients.
The researchers argued the previous PCOS name contributed directly to diagnostic delays. With up to 70% of affected individuals remaining undiagnosed, the study found that the focus on “cysts” caused both patients and clinicians to overlook the metabolic and endocrine features that drive much of the condition’s long-term health burden.
That is why the renaming process — which collected feedback from more than 14,000 patients and health professionals through iterative surveys, workshops, modified Delphi consensus methods and implementation analyses — prioritized scientific accuracy alongside reduction of stigma and feasibility in clinical practice.
“While international guidelines have advanced awareness and care, a name change was the next critical step towards recognition and improvement in the long-term impacts of this condition,” Teede said.
The consortium concluded that “Polyendocrine Metabolic Ovarian Syndrome” better reflects the condition as a multisystem hormonal and metabolic disorder rather than a disease defined primarily by ovarian cysts.
What The PMOS Update Means For Patients
For patients seeking a diagnosis, the practical implications are significant. Because PMOS can present with metabolic complications such as insulin resistance, cardiovascular risk and fatty liver disease, in addition to reproductive and dermatological symptoms, care often requires input from multiple specialists — including endocrinologists, gynecologists and primary care providers.
The Lancet paper outlines a planned multiyear transition strategy involving updates to medical guidelines, patient education materials and international disease classification systems. That means the change from PCOS to PMOS will not happen overnight in clinics, insurance coding or patient-facing health literature, but the global infrastructure for the transition is now being built.
“This is a landmark moment that will lead to desperately needed worldwide advancements in clinical practice and research,” Teede said.
This article was created by content specialists using various tools, including AI.
